# DR-01

Source: https://onco.cc/drugs/dr-01/  
OnCo record `dr-01` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DR-01 is a monoclonal antibody from Dren Bio, in registered phase 2 trials for peripheral T-cell lymphomas.

## Summary

DR-01 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Dren Bio, in peripheral T-cell lymphomas. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: DR-01
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody, as described in the registry record.

## Sources

- ClinicalTrials.gov: trials of DR-01: https://clinicaltrials.gov/search?intr=DR-01

## Connected records

- cancers: [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- trials: [A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas](https://onco.cc/trials/nct05475925/)

---
JSON: https://onco.cc/api/v1/entities/dr-01.json